Table 4.
Correlation between Mutational Status of RET and RAS Genes with Clinical and Pathological Features of the Primary sMTC Cases
| RET M918T | RET Other | RAS | Not RET/Not RAS | p Value | |
| Sex | 0.1378a | ||||
| Female | 51.2% (22/43) | 52.8% (19/36) | 72.5%(29/40) | 67.9% (19/28) | |
| Male | 48.8% (21/43) | 47.2% (17/36) | 27.5% (11/40) | 32.1% (9/28) | |
| Age at diagnosis (mean ± SD) (years) | 49.43 ± 13.93 | 55.67 ± 14.32 | 55.81 ± 15.44 | 58.84 ± 15.70 | 0.0779b |
| Primary/metastases | 0.1609a | ||||
| Primary | 74.1% (43/58) | 83.7% (36/43) | 90.9% (40/44) | 84.8% (28/33) | |
| Metastases | 25.9% (15/58) | 16.3% (7/43) | 9.1% (4/44) | 15.2% (5/33) | |
| Outcome | <0.0001a | ||||
| Disease-free | 26.3% (10/38) | 66.7% (20/30) | 61.8% (21/34) | 77.3% (17/22) | |
| Biochemical | 7.9% (3/38) | 6.7% (2/30) | 29.4% (10/34) | 9.1% (2/22) | |
| Metastatic/dead | 65.8% (25/38) | 26.6% (8/30) | 8.8% (3/34) | 13.6% (3/22) | |
| Stage | 0.0001a | ||||
| I | 18.9% (7/37) | 46.9% (15/32) | 62.5% (25/40) | 70.8% (17/24) | |
| III | 81.1% (30/37) | 53.1% (17/32) | 37.5% (15/40) | 29.2% (7/24) | |
| T Categories | <0.0001a | ||||
| T1+T2 | 37.1% (13/35) | 72.7% (24/33) | 90.0% (36/40) | 83.3% (20/24) | |
| T3+T4 | 62.9% (22/35) | 27.3% (9/33) | 10.0% (4/40) | 16.7% (4/24) | |
| Lymph-node metastasis (N) | 0.0021a | ||||
| N0 | 30.6% (11/36) | 54.5% (18/33) | 66.7% (26/39) | 75.0% (18/24) | |
| N1 | 69.4% (25/36) | 45.5% (15/33) | 33.3% (13/39) | 25.0% (6/24) | |
| Distant metastasis (M) | 0.0073a | ||||
| M0 | 77.8% (28/36) | 90.6% (29/32) | 97.5% (39/40) | 100.0% (24/24) | |
| M1 | 22.2% (8/36) | 9.4% (3/32) | 2.5% (1/40) | 0 (0/24) |
Unless stated, values are expressed in % (number/total number).
a
Chi-squared test.
b
One-way ANOVA test.